**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a report, 3 patients (2 women and 1 man) aged 53−76 years were described, who developed granulocytopenia with catatonia (1 patient), ileus (1 patient) or delirium (1 patient) due to clozapine toxicity while receiving clozapine for bipolar-type schizoaffective disorder or schizophrenia. Additionally, one of these patients also developed neutropenia during off-label therapy with tocilizumab for COVID-19 \[*routes and times to reactions onsets not stated*\].

Patient 1 (A 76-year-old man): The man, who had bipolar-type schizoaffective disorder, had been receiving clozapine 300mg every night. His previous clozapine trough level was 106 ng/mL. He also received monthly maintenance electroconvulsive therapy (ECT). He was hospitalised due to COVID-19 \[*aetiology not stated*\] and granulocytopenia with catatonia 1 month after missing the last ECT treatment. Since the hospitalisation, his clozapine trough level was found to be at toxic level (1360 ng/mL), consistent with clozapine toxicity. His granulocytopenia with catatonia was attributed to clozapine toxicity. He received off-label therapy with tocilizumab for COVID-19. He subsequently developed tocilizumab-associated neutropenia (nadir absolute neutrophil count of 1100). Thereafter, his absolute neutrophil count gradually increased to the 4000. During hospitalisation, he was also treated with lorazepam, and his clozapine dose was reduced to 200mg every night. Eventually, his catatonia resolved.

Patient 2 (A 63-year-old woman): The woman, who had bipolar-type schizoaffective disorder, had been receiving clozapine 50mg every morning and 350mg every night along with concurrent administration of citalopram and olanzapine. Her bipolar-type schizoaffective disorder remained stable for nearly a decade on these medications. Thereafter, she was admitted with confusion and nausea, and was eventually diagnosed with COVID-19 along with hyponatraemia \[*aetiology of these events not stated*\]. She was also diagnosed with ileus. At admission 4h before clozapine night dose, the clozapine level was found to be at toxic level (1060 ng/mL), consistent with clozapine toxicity. The development of the ileus was attributed to clozapine toxicity, and therefore, her clozapine therapy was withheld for 1 week without adverse consequences. Gradually, clozapine was reintroduced when her bowel function returned to normal.

Patient 3 (A 53-year-old woman): The woman, who had schizophrenia, had been receiving clozapine 250mg every night for many years along with concurrent administration of fluphenazine. Thereafter, she presented with delirium. She also had vomiting and fever. Following admission, she was diagnosed with COVID-19 \[*aetiology not stated*\]. Additionally, her clozapine trough level was found to be at toxic level (2154 ng/mL), consistent with clozapine toxicity. The development of the delirium was attributed to clozapine toxicity, and therefore, her clozapine dose was reduced to 50mg every night with a temporary increase fluphenazine dose. Following normalisation of the mental status, she gradually started receiving her clozapine 250mg every night.
